

IN THE SPECIFICATION:

Please amend the specification as follows:

At page 5, line 14, please insert a sequence identifier as follows:

--R<sub>1</sub>-Val-His-Phe-Phe-Lys-Asn-Ile-R<sub>2</sub> (SEQ ID NO:2)--

At page 5, line 23, please insert sequence identifiers as follows:

--Examples of said peptides are selected from (SEQ ID NOS:3 to 13):--

At page 9, line 15, please substitute an upper case letter as follows:

--Fig 11[[a]]A shows free--

At page 9, line 19, please substitute an upper case letter as follows:

--Fig 11[[b]]B shows free--

At page 9, line 24, please substitute the corresponding phrase with the following:

--Fig 11[[c]]C shows free--

At page 9, line 28, please substitute the corresponding phrase with the following:

--Fig 11[[d]]D shows free--

At page 12, line 14, please insert a sequence identifier as follows:

--R<sub>1</sub>-Val-His-Phe-Phe-Lys-Asn-Ile-R<sub>2</sub> (SEQ ID NO:2)--

At page 12, line 31, please insert a sequence identifier as follows:

--R<sub>1</sub>-Val-His-Phe-Phe-Lys-Asn-Ile-R<sub>2</sub> (SEQ ID NO:2)--

At page 13, line 12, please substitute the corresponding sequence identifier as follows:

--~~SEQ ID NO:1~~ SEQ ID NO:1--

RECEIVED  
DEC 09 2003  
OFFICE OF PETITIONS

RECEIVED

DEC 24 2003

TECH CENTER 1600/2900

At page 13, line 17, please substitute the corresponding sequence identifier as follows:

~~SEQ ID NO:1~~ SEQ ID NO:1--

At page 13, lines 20-21, please insert a sequence identifier as follows:

~~Val-His-Phe-Phe-Lys-Asn-Ile~~ (SEQ ID NO:2)--

At page 15, line 1, please substitute sequence identifier "SEQ ID NO:1" as follows:

~~SEQ ID NO:1~~ SEQ ID NO:14 (amino acids 61 to 106 of SEQ ID NO:1)--

RECEIVED  
DEC 09 2003

OFFICE OF PETITIONS

At page 15, line 7, please insert sequence identifiers as follows:

--Examples of peptides are selected from the group consisting of (SEQ ID NOS:5, 4, 6, 3, 7 and 8, respectively):--

At page 15, line 25, please insert a sequence identifier as follows:

--R<sub>1</sub>-Val-His-Phe-Phe-Lys-Asn-Ile-R<sub>2</sub> (SEQ ID NO:2)--

RECEIVED

DEC 24 2003

At page 16, line 1, please insert sequence identifiers as follows:

--Examples of peptides are selected from (SEQ ID NOS:9 to 13):--

TECH CENTER 1600/2900

At page 20, lines 21-23, please capitalize the trademark as follows:

--IgG was purified from concentrated CSF of patients with acute MS by protein A-Sepharose (Pharmacia PHARMACIA<sup>TM</sup>) affinity chromatography as previously described--

At page 20, lines 29-30, please capitalize the trademark as follows:

--Purified MBP was coupled to CNBr-activated Sepharose 4B (Pharmacia PHARMACIA<sup>TM</sup>) according to the manufacturer's instructions--

At page 35, lines 11-12, please substitute an upper case letter as follows:

--One of these patients (Figure 11[[a]]A) received--

At page 35, line 24, please substitute an upper case letter as follows:

--four daily injections (Figure 11[[b]]B: it#1, it#2, it#3, it#4)--

At page 36, line 2, please substitute an upper case letter as follows:

-- Figure 11[[c]]C illustrates the anti-MBP profile--

At page 36, line 13, please substitute an upper case letter as follows:

-- injection (Figure 11[[d]]D: it#1, it#2, it#3, it#4) and 10 days--